To the Editor
Patients with mental illness are at an elevated risk for developing cataracts when compared to the general population. This effect is multifactorial and corresponds to higher rates of smoking, alcohol use disorder, and hypertension (Souza VB et al., 2008). There is evidence that first generation antipsychotics increase the risk of cataracts, however data about second-generation antipsychotics is limited and consists mainly of case reports involving quetiapine (Souza VB et al., 2008; Laties AM et al., 2015). There is only one case report associating risperidone with cataracts (Dsouza MC, 2015) in addition to one large-scale study comparing the cataractogenic potential of quetiapine versus risperidone (Laties AM et al., 2015). Our goal is to add to the current evidence base by reporting a case of an otherwise healthy young individual who developed cataracts while on risperidone.
OD is a 27-year-old male, with no medical comorbidities, who has a diagnosis of ADHD and Bipolar disorder. Since age ten, the patient was treated with methylphenidate and valproic acid, however at the age of sixteen, he started displaying symptoms of psychosis. After a failed trial of quetiapine 400mg/day for a few months, the patient was put on risperidone 6mg/day. At the same time, valproic acid and methylphenidate were discontinued, and lithium 900mg/day was initiated with good response.
The patient first complained of blurry vision at age 26 and saw an optometrist who discovered cataracts in both eyes with 20/40 vision. The patients last recorded vision was 20/20 documented at age 24. The patient was referred to an ophthalmologist, who diagnosed grade three cataracts of the left eye and trace cataracts of the right eye, indicating bilateral asymmetrical cataracts. Given ongoing blurry vision, he opted for cataract surgery of the left eye. A later eye examination revealed no further changes in the right eye cataract.
To our knowledge, this is the second case showing a potential association between cataracts and risperidone. Our patient has a lack of risk factors including no metabolic abnormalities, a normal baseline eye examination and no prior history of cataracts. Although the patient was exposed to quetiapine and valproic acid, the exposure to those medications was for shorter periods of time. Moreover, the patient had an unremarkable eye examination several years after discontinuing quetiapine and valproic acid. Given that there are no reports indicating a relationship between lithium and cataract formation, we suggest that risperidone has contributed to the patient’s cataract formation.
Acknowledgments
Funding
This study was supported in parts by The National Institute of Mental Health [grant number K23MH100264].
Footnotes
Declaration of interest
The authors declare that there is no conflict of interest. The authors alone are responsible for the content and writing of the paper.
References
- 1.Dsouza MC. Could Risperidone Have Caused the Cataract?: A Case Report and Review of Literature. Journal of Research in Psychiatry and Behavioral Science. 2015;1(1):25–26. [Google Scholar]
- 2.Laties AM, Flach AJ, Baldycheva I, et al. Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: A randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. Journal of Psychopharmacology. 2015;29(1):69–79. doi: 10.1177/0269881114553253. [DOI] [PubMed] [Google Scholar]
- 3.Souza VB, Moura Filho FJ, Souza FG, et al. Cataract occurrence in patients treated with antipsychotic drugs. Revista Brasileira de Psiquiatria. 2008;30(3):222–6. doi: 10.1590/s1516-44462008000300008. [DOI] [PubMed] [Google Scholar]